![\"A](\"https:\/\/hudson.org.au\/wp-content\/uploads\/2017\/01\/081_Patrick-Western_20180412-320x320.jpg\")
<\/div>\n Understanding non-genetic inheritance in health and disease<\/h3>\n \n Associated Professor Patrick Western<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,433,936<\/p>\n <\/div>\n <\/div>\n
\n Eggs provide genetic and non-genetic (epigenetic) information that is critical for offspring development. While it is understood how genes transmit instructions that regulate offspring development, epigenetic inheritance is poorly understood. This project will determine how an essential epigenetic mechanism acting in eggs controls formation of tissues in offspring and grand-offspring and how dysregulation of this mechanism results in disease. Outcomes will help understand disease inheritance.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n ![\"Dr](\"https:\/\/hudson.org.au\/wp-content\/uploads\/2019\/08\/Kelly-Crossley-320x320.jpg\")
<\/div>\n \n Reducing the burden of respiratory distress after caesarean delivery<\/h3>\n \n Dr Kelly Crossley<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,240,465<\/p>\n <\/div>\n <\/div>\n
\n Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. The team have recently made a major break-through in understanding why, and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of newborn breathing problems.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n ![\"Dr](\"https:\/\/hudson.org.au\/wp-content\/uploads\/2021\/08\/Associate-Professor-Michael-Gantier-320x320.jpeg\")
<\/div>\n \n Therapeutic targeting of TLR7 in autoimmunity<\/h3>\n \n Associate Professor Michael Gantier<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,496,654<\/p>\n <\/div>\n <\/div>\n
\n Autoimmune diseases affect approximately five per cent of Australians and are driven by autoantibodies. While treatments are available to limit disease progression and morbidity, these are non-curative and have numerous side-effects. The team propose an innovative approach to tackle the management of autoimmunity by targeting how auto-antibodies are generated. A new class of highly-specific therapeutics has been generated that have the potential to help management of diverse autoimmune conditions.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n ![\"Fiona](\"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/03\/Fiona-Cousins-Pic-320x320.jpg\")
<\/div>\n \n Harnessing the protective effects of Interferon epsilon as a therapeutic target for endometriosis<\/h3>\n \n Dr Fiona Cousins<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,125,386<\/p>\n <\/div>\n <\/div>\n
\n Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFN\u03b5), which may exert protective effects against the development of endometriosis. The team will investigate whether IFN\u03b5 \u00a0can be used as an innovative treatment for endometriosis.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n ![\"Associate](\"https:\/\/hudson.org.au\/wp-content\/uploads\/2022\/06\/Assoc-Prof-Michelle-Tate-Influenza-Home-Page-320x320.jpg\")
<\/div>\n \n Targeting pyroptosis to limit the severity of influenza virus infections<\/h3>\n \n Associate Professor Michelle Tate<\/h4>\n <\/a>\n
NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
Amount: $1,433,936<\/p>\n <\/div>\n <\/div>\n
Eggs provide genetic and non-genetic (epigenetic) information that is critical for offspring development. While it is understood how genes transmit instructions that regulate offspring development, epigenetic inheritance is poorly understood. This project will determine how an essential epigenetic mechanism acting in eggs controls formation of tissues in offspring and grand-offspring and how dysregulation of this mechanism results in disease. Outcomes will help understand disease inheritance.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
<\/div>\n Reducing the burden of respiratory distress after caesarean delivery<\/h3>\n \n Dr Kelly Crossley<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,240,465<\/p>\n <\/div>\n <\/div>\n
\n Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. The team have recently made a major break-through in understanding why, and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of newborn breathing problems.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Therapeutic targeting of TLR7 in autoimmunity<\/h3>\n \n Associate Professor Michael Gantier<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,496,654<\/p>\n <\/div>\n <\/div>\n
\n Autoimmune diseases affect approximately five per cent of Australians and are driven by autoantibodies. While treatments are available to limit disease progression and morbidity, these are non-curative and have numerous side-effects. The team propose an innovative approach to tackle the management of autoimmunity by targeting how auto-antibodies are generated. A new class of highly-specific therapeutics has been generated that have the potential to help management of diverse autoimmune conditions.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Harnessing the protective effects of Interferon epsilon as a therapeutic target for endometriosis<\/h3>\n \n Dr Fiona Cousins<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,125,386<\/p>\n <\/div>\n <\/div>\n
\n Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFN\u03b5), which may exert protective effects against the development of endometriosis. The team will investigate whether IFN\u03b5 \u00a0can be used as an innovative treatment for endometriosis.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Targeting pyroptosis to limit the severity of influenza virus infections<\/h3>\n \n Associate Professor Michelle Tate<\/h4>\n <\/a>\n
NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
Amount: $1,240,465<\/p>\n <\/div>\n <\/div>\n
Compared with vaginally born babies, babies born at term by caesarean section have a higher risk of needing intensive care due to breathing problems soon after birth. The team have recently made a major break-through in understanding why, and this project will provide the additional information required to identify effective treatments for these otherwise healthy newborns. Ultimately this research will identify approaches and treatments that will reduce the risk or severity of newborn breathing problems.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
<\/div>\n Therapeutic targeting of TLR7 in autoimmunity<\/h3>\n \n Associate Professor Michael Gantier<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,496,654<\/p>\n <\/div>\n <\/div>\n
\n Autoimmune diseases affect approximately five per cent of Australians and are driven by autoantibodies. While treatments are available to limit disease progression and morbidity, these are non-curative and have numerous side-effects. The team propose an innovative approach to tackle the management of autoimmunity by targeting how auto-antibodies are generated. A new class of highly-specific therapeutics has been generated that have the potential to help management of diverse autoimmune conditions.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Harnessing the protective effects of Interferon epsilon as a therapeutic target for endometriosis<\/h3>\n \n Dr Fiona Cousins<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,125,386<\/p>\n <\/div>\n <\/div>\n
\n Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFN\u03b5), which may exert protective effects against the development of endometriosis. The team will investigate whether IFN\u03b5 \u00a0can be used as an innovative treatment for endometriosis.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Targeting pyroptosis to limit the severity of influenza virus infections<\/h3>\n \n Associate Professor Michelle Tate<\/h4>\n <\/a>\n
NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
Amount: $1,496,654<\/p>\n <\/div>\n <\/div>\n
Autoimmune diseases affect approximately five per cent of Australians and are driven by autoantibodies. While treatments are available to limit disease progression and morbidity, these are non-curative and have numerous side-effects. The team propose an innovative approach to tackle the management of autoimmunity by targeting how auto-antibodies are generated. A new class of highly-specific therapeutics has been generated that have the potential to help management of diverse autoimmune conditions.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
<\/div>\n Harnessing the protective effects of Interferon epsilon as a therapeutic target for endometriosis<\/h3>\n \n Dr Fiona Cousins<\/h4>\n <\/a>\n \n \n NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
\n Amount: $1,125,386<\/p>\n <\/div>\n <\/div>\n
\n Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFN\u03b5), which may exert protective effects against the development of endometriosis. The team will investigate whether IFN\u03b5 \u00a0can be used as an innovative treatment for endometriosis.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
\n\n \n \n \n <\/div>\n \n Targeting pyroptosis to limit the severity of influenza virus infections<\/h3>\n \n Associate Professor Michelle Tate<\/h4>\n <\/a>\n
NHMRC Ideas Grant: 2022\u20132026<\/p>\n <\/div>\n
Amount: $1,125,386<\/p>\n <\/div>\n <\/div>\n
Endometriosis is a chronic, debilitating condition that affects one in nine menstruators. People with the disease have limited treatment options and there is no cure. A defective immune response is one of the causes of the disease. This project aims to investigate a new immunomodulator, interferon epsilon (IFN\u03b5), which may exert protective effects against the development of endometriosis. The team will investigate whether IFN\u03b5 \u00a0can be used as an innovative treatment for endometriosis.<\/p>\n
<\/p>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n \n
<\/div>\n